B-intervention	0	10	Epirubicin
I-intervention	10	11	-
I-intervention	11	16	based
I-intervention	17	29	chemotherapy
O	30	32	as
O	33	41	adjuvant
O	42	51	treatment
O	52	55	for
O	56	60	poor
O	61	70	prognosis
O	70	71	,
O	72	76	node
O	76	77	-
O	77	85	negative
O	86	92	breast
O	93	99	cancer
O	99	100	:
O	101	103	10
O	103	104	-
O	104	108	year
O	109	115	follow
O	115	116	-
O	116	118	up
O	119	126	results
O	127	129	of
O	130	133	the
O	134	140	French
O	141	149	Adjuvant
O	150	155	Study
O	156	161	Group
O	162	164	03
O	165	170	trial
O	170	171	.

O	172	174	We
O	175	184	evaluated
O	185	188	the
O	189	201	contribution
O	202	204	of
O	205	207	an
O	208	218	epirubicin
O	218	219	-
O	219	224	based
O	225	233	adjuvant
O	234	246	chemotherapy
O	247	249	on
O	250	257	disease
O	257	258	-
O	258	262	free
O	263	271	survival
O	272	273	(
O	273	276	DFS
O	276	277	)
O	278	280	in
O	281	285	poor
O	286	295	prognosis
O	295	296	,
B-eligibility	297	301	node
I-eligibility	301	302	-
I-eligibility	302	310	negative
I-eligibility	311	317	breast
I-eligibility	318	324	cancer
I-eligibility	325	326	(
I-eligibility	326	328	BC
I-eligibility	328	329	)
I-eligibility	330	338	patients
O	338	339	.

O	340	344	Poor
O	345	355	prognostic
O	356	363	factors
O	364	368	were
O	369	376	defined
O	377	379	as
O	379	380	:
O	381	391	pathologic
O	392	397	tumor
O	398	402	size
O	403	404	>
O	404	406	or
O	406	407	=
O	408	409	4
O	410	412	cm
O	412	413	,
O	414	422	estrogen
O	422	423	-
O	423	431	receptor
O	432	440	negative
O	440	441	,
O	442	445	and
O	446	458	progesterone
O	458	459	-
O	459	467	receptor
O	468	476	negative
O	476	477	.

O	478	484	Scarff
O	484	485	-
O	485	490	Bloom
O	491	501	Richardson
O	502	507	grade
O	508	509	2
O	510	516	tumors
O	517	521	must
O	522	526	have
O	527	530	two
O	531	533	of
O	534	539	these
O	540	547	factors
O	547	548	,
O	549	552	and
O	553	557	only
O	558	561	one
O	562	564	in
O	565	569	case
O	570	572	of
O	573	578	grade
O	579	580	3
O	580	581	.

O	582	589	Between
O	590	594	1988
O	595	598	and
O	599	603	1994
O	603	604	,
B-total-participants	605	608	328
O	609	617	patients
O	618	622	were
O	623	633	randomized
O	634	636	to
O	637	644	receive
O	645	651	either
B-control	652	654	no
I-control	655	663	systemic
I-control	664	673	treatment
I-control	674	675	(
I-control	675	682	control
O	682	683	,
O	684	685	n
O	686	687	=
B-control-participants	688	691	161
O	691	692	)
O	692	693	,
O	694	696	or
O	697	709	fluorouracil
O	710	713	500
O	714	716	mg
O	716	717	/
O	717	718	m
O	718	719	(
O	719	720	2
O	720	721	)
O	721	722	,
O	723	733	epirubicin
O	734	736	50
O	737	739	mg
O	739	740	/
O	740	741	m
O	741	742	(
O	742	743	2
O	743	744	)
O	744	745	,
O	746	762	cyclophosphamide
O	763	766	500
O	767	769	mg
O	769	770	/
O	770	771	m
O	771	772	(
O	772	773	2
O	773	774	)
O	774	775	,
O	776	777	6
O	778	784	cycles
O	785	790	every
O	791	793	21
O	794	798	days
O	799	800	(
O	800	805	FEC50
O	805	806	,
O	807	808	n
O	809	810	=
B-intervention-participants	811	814	167
O	814	815	)
O	815	816	,
O	817	824	without
O	825	828	any
O	829	837	hormonal
O	838	847	treatment
O	847	848	.

O	849	852	The
O	853	859	median
O	860	866	follow
O	867	869	up
O	870	873	was
O	874	877	114
O	878	884	months
O	884	885	.

O	886	889	The
B-outcome	890	892	10
I-outcome	892	893	-
I-outcome	893	897	year
I-outcome	898	901	DFS
I-outcome	902	907	rates
O	908	912	were
B-cv-bin-percent	913	915	64
O	916	919	and
B-iv-bin-percent	920	922	71
I-iv-bin-percent	922	923	%
O	923	924	,
O	925	937	respectively
O	938	939	(
O	939	940	p
O	941	942	=
O	943	944	0
O	944	945	.
O	945	947	23
O	947	948	)
O	948	949	.

O	950	952	In
O	953	956	the
O	957	960	Cox
O	961	971	regression
O	972	977	model
O	977	978	,
O	979	990	independent
O	991	1001	prognostic
O	1002	1009	factors
O	1010	1012	of
O	1013	1020	relapse
O	1021	1025	were
O	1026	1029	the
O	1030	1036	number
O	1037	1039	of
O	1040	1045	nodes
O	1046	1054	examined
O	1055	1056	<
O	1057	1059	10
O	1060	1061	(
O	1061	1062	p
O	1063	1064	=
O	1065	1066	0
O	1066	1067	.
O	1067	1070	002
O	1070	1071	)
O	1071	1072	,
O	1073	1076	BCS
O	1077	1078	(
O	1078	1079	p
O	1080	1081	=
O	1082	1083	0
O	1083	1084	.
O	1084	1086	01
O	1086	1087	)
O	1087	1088	,
O	1089	1092	and
O	1093	1106	premenopausal
O	1107	1113	status
O	1114	1115	(
O	1115	1116	p
O	1117	1118	=
O	1119	1120	0
O	1120	1121	.
O	1121	1123	04
O	1123	1124	)
O	1124	1125	.

O	1126	1128	In
O	1129	1133	this
O	1134	1139	model
O	1139	1140	,
O	1141	1144	the
O	1145	1153	relative
B-outcome	1154	1158	risk
I-outcome	1159	1161	of
I-outcome	1162	1169	relapse
O	1170	1173	was
O	1174	1175	1
O	1175	1176	.
O	1176	1178	46
O	1179	1180	(
O	1180	1184	CI95
O	1185	1186	%
O	1186	1187	:
O	1188	1189	1
O	1189	1190	.
O	1190	1192	05
O	1192	1193	-
O	1193	1194	1
O	1194	1195	.
O	1195	1197	87
O	1197	1198	)
O	1199	1201	in
O	1202	1207	favor
O	1208	1210	of
O	1211	1216	FEC50
O	1216	1217	.

O	1218	1220	In
O	1221	1229	patients
O	1230	1233	who
O	1234	1243	underwent
O	1244	1247	BCS
O	1247	1248	,
O	1249	1251	21
O	1252	1253	%
O	1254	1263	developed
O	1264	1265	a
B-outcome	1266	1271	local
I-outcome	1272	1279	relapse
O	1280	1281	(
B-cv-bin-percent	1281	1283	24
O	1284	1290	versus
B-iv-bin-percent	1291	1293	18
I-iv-bin-percent	1294	1295	%
O	1295	1296	,
O	1297	1309	respectively
O	1309	1310	)
O	1310	1311	.

O	1312	1315	The
B-outcome	1316	1318	10
I-outcome	1318	1319	-
I-outcome	1319	1323	year
I-outcome	1324	1329	local
I-outcome	1330	1333	DFS
O	1334	1337	was
B-cv-bin-percent	1338	1340	70
I-cv-bin-percent	1340	1341	.
I-cv-bin-percent	1341	1342	5
O	1343	1346	and
B-iv-bin-percent	1347	1349	79
I-iv-bin-percent	1349	1350	.
I-iv-bin-percent	1350	1351	3
I-iv-bin-percent	1352	1353	%
O	1353	1354	,
O	1355	1367	respectively
O	1368	1369	(
O	1369	1370	p
O	1371	1372	=
O	1373	1374	0
O	1374	1375	.
O	1375	1377	27
O	1377	1378	)
O	1378	1379	.

O	1380	1383	The
B-outcome	1384	1386	10
I-outcome	1386	1387	-
I-outcome	1387	1391	year
I-outcome	1392	1399	overall
I-outcome	1400	1408	survival
O	1409	1412	was
O	1413	1416	not
O	1417	1426	different
O	1427	1428	(
B-cv-bin-percent	1428	1430	74
I-cv-bin-percent	1430	1431	.
I-cv-bin-percent	1431	1432	1
O	1433	1439	versus
B-iv-bin-percent	1440	1442	70
I-iv-bin-percent	1442	1443	.
I-iv-bin-percent	1443	1444	7
I-iv-bin-percent	1445	1446	%
O	1446	1447	,
O	1448	1449	p
O	1450	1451	=
O	1452	1453	0
O	1453	1454	.
O	1454	1456	82
O	1456	1457	)
O	1457	1458	.

O	1459	1464	After
O	1465	1467	10
O	1468	1473	years
O	1474	1476	of
O	1477	1483	follow
O	1483	1484	-
O	1484	1486	up
O	1486	1487	,
O	1488	1491	the
O	1492	1497	FEC50
O	1498	1505	regimen
O	1506	1513	reduced
O	1514	1517	the
B-outcome	1518	1522	risk
I-outcome	1523	1525	of
I-outcome	1526	1533	relapse
O	1534	1536	in
O	1537	1541	poor
O	1541	1542	-
O	1542	1551	prognosis
O	1552	1556	node
O	1556	1557	-
O	1557	1565	negative
O	1566	1568	BC
O	1569	1577	patients
O	1577	1578	.

O	1579	1582	The
B-outcome	1583	1592	incidence
I-outcome	1593	1595	of
I-outcome	1596	1601	local
I-outcome	1602	1609	relapse
O	1610	1613	was
O	1614	1618	high
O	1618	1619	,
O	1620	1623	and
O	1624	1632	probably
O	1633	1640	related
O	1641	1643	to
O	1644	1653	inclusion
O	1654	1662	criteria
O	1662	1663	.

O	1664	1674	Epirubicin
O	1675	1678	was
O	1679	1687	probably
O	1688	1698	underdosed
O	1699	1701	in
O	1702	1706	such
O	1707	1715	patients
O	1715	1716	,
O	1717	1720	and
O	1721	1728	ongoing
O	1729	1736	studies
O	1737	1742	using
O	1743	1746	100
O	1747	1749	mg
O	1749	1750	/
O	1750	1751	m
O	1751	1752	(
O	1752	1753	2
O	1753	1754	)
O	1755	1757	of
O	1758	1768	epirubicin
O	1769	1773	will
O	1774	1778	give
O	1779	1781	us
O	1782	1785	the
O	1786	1792	answer
O	1793	1795	in
O	1796	1797	a
O	1798	1802	near
O	1803	1809	future
O	1809	1810	.
